Skip to content

Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception

Depo-Provera: Evaluation of Bone Mineral Density and Total Body Calcium in Adolescent DP 150 CI Users and Matched Controls

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00139685
Enrollment
350
Registered
2005-08-31
Start date
1998-04-30
Completion date
2007-07-31
Last updated
2008-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Density, Contraception

Brief summary

To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and following discontinuation of DMPA. Another group electing non-hormonal contraception or abstinence will be recruited as a reference population, across all study sites. The primary variable is BMD, measured by Dual Energy X-ray Absorptiometry (DXA). Secondary variables are: Total Body Composition& Total Body Calcium (TBC), measured by Dual Energy X-ray Absorptiometry (DXA), and surrogate biologic BMD markers. Safety will be evaluated by adverse event reporting, laboratory evaluations, pregnancies, weight and vital signs.

Interventions

DRUGDepo-Provera Contraceptive Injection - DP150CI

Sponsors

Pfizer
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
12 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Adolescent females who have had any menses in the 6 months prior to enrollment * Must have a negative pregnancy test

Exclusion criteria

* Concomitant medication exclusion use of bone modifying agents, glucocorticoids, heparin, and anticonvulsants * Screening Spinal BMD with z score not greater than -2 of matched young normals

Design outcomes

Primary

MeasureTime frame
recruited as a reference population, across all study sites.
Injection (DP150CI) users will be evaluated and compared during depo
medroxyprogesterone acetate (DMPA) therapy and following discontinuation of
DMPA.Another group electing non-hormonal contraception or abstinence is
Changes in Bone Mineral Density in adolescent Depo-Provera Contraceptive

Secondary

MeasureTime frame
measured by Dual Energy X-ray Absorptiometry (DXA)Surrogate biologic BMD
markers
Secondary variables are: Total Body Composition & Total Body Calcium (TBC),

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026